Positive CHMP opinion on Slenyto® for the treatment of Insomnia in children with Neurogenetic Disorders (NGDs)

We are excited to announce that Neurim Pharmaceuticals received a positive CHMP opinion on Slenyto ® (Pediatric Prolonged-Release Melatonin) for the treatment of Insomnia in children with Neurogenetic Disorders (NGDs). This treatment will address additional patients who may benefit with Slenyto ® added indication and have good nights and better days. Read our press release

The release as fetched from its publisher. neurim.com ↗